Overview

The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of erenumab in calcitonin-gene related peptide and cilostazol experimental models of migraine in humans. Followed by a 6-month open-label extension.

Phase:

N/A

Details

Lead Sponsor:

Danish Headache Center

Collaborator:

Novartis Pharmaceuticals

Treatments:

Calcitonin
Calcitonin Gene-Related Peptide
Cilostazol
Erenumab
Katacalcin
Salmon calcitonin